NICE has given the nod to Roche’s Perjeta for routine first-line use, alongside Herceptin and chemotherapy, in patients with HER2-positive breast cancer.
The drug has been available on the Cancer Drug Fund but the successful price negotiations between Roche and NHS England means that all patients will be offered the drug as standard.
The use of Perjeta has been found to increase overall survival, on average, by 16 months, as well as improving the numbers of patients whose cancer did not recur from 90.6% to 92.3%.
